Characterization of the ascending colon fluids in ulcerative colitis

Pharmaceutical Research

Volumn 27, Issue 8, 2010, Pages 1620-1626

  Vertzoni, Maria ^a   Goumas, Konstantinos ^b   Söderlind, Erik ^c   Abrahamsson, Bertil ^c   Dressman, Jennifer B ^d   Poulou, Androniki ^b   Reppas, Christos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b RED CROSS HOSPITAL   (Greece)

^c ASTRAZENECA R AND D   (Sweden)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

ascending colon; colonic targeting; lumenal composition; ulcerative colitis

Indexed keywords

AZATHIOPRINE; BACLOFEN; BILE ACID; CARBOHYDRATE DERIVATIVE; CHOLESTEROL; DIACYLGLYCEROL; ENEMA; ISOBUTYRIC ACID; LONG CHAIN FATTY ACID; MESALAZINE; MONOACYLGLYCEROL; PANTOPRAZOLE; PHOSPHATIDYLCHOLINE; PREDNISOLONE; PROTEIN; SHORT CHAIN FATTY ACID; TIZANIDINE; TRIACYLGLYCEROL; FATTY ACID;

ADULT; ARTICLE; ASCENDING COLON; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; FEMALE; HUMAN; INTESTINE FLUID; MALE; OSMOLARITY; PH; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; ULCERATIVE COLITIS; ADOLESCENT; CHEMISTRY; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; SOLUBILITY; STOMACH JUICE; YOUNG ADULT;

ADOLESCENT; ADULT; CHOLESTEROL; COLITIS, ULCERATIVE; COLON, ASCENDING; FATTY ACIDS; FEMALE; GASTROINTESTINAL CONTENTS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; RECURRENCE; SOLUBILITY; YOUNG ADULT;

EID: 77955466001     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0158-y     Document Type: Article

References (28)

1. Wilson CG, Weitschies W, Butler J. Gastrointestinal transit and drug absorption. In: Dressman J, Reppas C, editors. Oral drug absorption, Informa Healthcare, New York, USA; 2010. pp. 41-65.
2. Milovic V, Stein J. Gastrointestinal disease and dosage form performance. In: Dressman J, Reppas C, editors. Oral drug absorption, Informa Healthcare, New York, USA; 2010. pp.127-139.
3. AV Sadfi RD Cohen 2007 Increasing the dose of oral mesalazine therapy for active unlcerative colitis does not improve remission rates Aliment Pharmacol Ther 26 1179 86
4. AM Metcalf SF Phillips AR Zinsmeister RL MacCarty RW Beart BG Wolff 1987 Simplified assessment of segmental colonic transit Gastroenterology 92 40 7 3023168
5. C Schiller C-P Froehlich T Giessmann W Siegmund H Moennikes N Hosten, et al. 2005 Intestinal fluid volumes and transit of dosage forms as assessed by numeric resonance imaging Aliment Pharmacol Ther 22 971 9 10.1111/j.1365-2036. 2005.02683.x 16268972 (Pubitemid 41634879)
6. SG Nugent D Kumar DS Rampton DF Evans 2001 Intestinal luminal pH in inflammatory disease: possible determinants and implications for therapy with aminosalicylates and other drugs Gut 48 571 7 10.1136/gut.48.4.571 11247905 (Pubitemid 32234805)
7. A Diakidou M Vertzoni K Goumas E Söderlind B Abrahamsson J Dressman, et al. 2009 Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults Pharm Res 26 2141 51 10.1007/s11095-009-9927-x 19572187
8. D Rachmilewitz 1989 Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial Br. Med. J. 298 82 6 10.1136/bmj.298.6666.82
9. O Hernell JE Staggers MC Carey 1990 Physical-chemical behaviour of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings Biochemistry 29 2041 56 10.1021/bi00460a012 2328238
10. GT MacFarlane S MacFarlane GR Gibson 1998 Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon Microb Ecol 35 180 7 10.1007/s002489900072 9541554 (Pubitemid 28190244)
11. JH Apajalahti LK Saerkilahti BR Maeki JP Heikkinen PH Nurminen WE Holben 1998 Effective recovery of bacterial DNA and percent-guanine-plus-cytosine-based analysis of community structure in the gastrointestinal tract of broiler chickens Applied Environ Microbiol 64 4084 8
12. GL Chan GR Erdmann SA Gruber AJ Matas DM Canafax 1990 Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients J Clin Pharmacol 30 358 63 2341582
13. JL Maddocks 1979 Assay of azathioprine, 6-mercaptopurine and a novel thiopurine metabolite in human plasma Br J Clin Pharmacol 8 273 8 40585
14. MA Pue J Laroche I Meineke C de Mey 1993 Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects Eur J Clin Pharmacol 44 575 8 10.1007/BF02440862 8405016
15. JT Backman MJ Karjalainen M Neuvonen J Laitila PJ Neuvonen 2006 Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects Br J Clin Pharmacol 62 345 57 10.1111/j.1365-2125. 2006.02653.x 16934051 (Pubitemid 44215535)
16. MN Martinez AJ Jackson 1991 Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-inf) Pharm Res 8 512 7 10.1023/A:1015863530888 1871049
17. SW Carson KJ Letrent M Kotlyar G Foose ME Tancer 2004 Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression Pharmacotherapy 24 482 7 10.1592/phco.24.5.482.33344 15098802 (Pubitemid 38420535)
18. P Vernia A Gnaedinger W Hauck RI Breuer 1988 Organic anions and the diarhea of the inflammatory bowel disease Dig Dis Sci 33 1353 8 10.1007/BF01536987 3180970 (Pubitemid 19011525)
19. K Grzybowska K Gwoździński G Zaleśna A Kisiel P Grzybowski I Płaneta-Małecka 2004 Mucus physicochemical properties in children with ulcerative colitis Pol Merkur Lekarski 17 S19 21
20. RL Bryan J Newman J Alexander-Williams 1990 Giant inflammatory polyposis in ulcerative colitis presenting with protein losing enteropathy J Clin Pathol 43 346 7 10.1136/jcp.43.4.346-b 2341571
21. R Anderson IT Kaariainen SB Hanauer 1996 Protein-losing enteropathy and massive pulmonary embolism in a patient with giant inflammatory polyposis and quiescent ulcerative colitis The Am J Med 101 323 5 10.1016/S0002-9343(96)00201- X (Pubitemid 26392446)
22. RD Pullan GAO Thomas M Rhodes, et al. 1994 Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis Gut 35 353 9 10.1136/gut.35.3.353 8150346
23. T Yamamoto Y Maruyama S Umegae K Matsumoto AR Saniabadi 2008 Mucosal inflammation in the terminal ileum of ulcerative colitis patients: endoscopic findings and cytokine profiles Dig Liver Dis 40 253 9 10.1016/j.dld.2007.11.020 18243079
24. JD Schulzke S Ploeger M Amasheh A Fromm S Zeissig H Troeger, et al. 2009 Ann NY Acad Sci 1165 294 300 10.1111/j.1749-6632.2009.04062.x 19538319
25. P Vernia R Caprilli G Latella F Berbetti FM Magliocca M Cittadini 1988 Fecal lactate and ulcerative colitis Gastroenterology 95 1564 8 3181680
26. TA Miettinen 1971 The role of bile salts in diarrhoea of patients with ulcerative colitis Gut 12 632 5 10.1136/gut.12.8.632 18668831
27. B Reddy C Martin E Wynder 1977 Feacal bile acids and cholesterol metabolites of patients with ulcerative colitis, a high-risk group for development of colon cancer Cancer Res 37 1697 701 322859
28. Abrahamsson B, Söderlind E. Screening modified release oral formulations in pharmaceutical industry. In: Dressman J, Reppas C, editors. Oral drug absorption, Informa Healthcare, New York, USA; 2010. pp. 267-97.